Previous 10 | Next 10 |
home / stock / rkv:cc / rkv:cc news
2024-03-27 17:08:02 ET Developing precision medicines that selectively target and kill cancer cells using leading-edge science to discover and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types. Rakovina Therapeutics Inc...
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response ...
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced f...
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response inhibitors (DDRi) to address high unmet medical needs in the treatment of cance...
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response (DDR) inhibitors to address high unmet medical needs in the treatment of cancer...
--News Direct-- Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report. Bacha highlighted several significant developments for the company during this perio...
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced f...
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of...
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced fi...
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“ Rakovina ” or the “ Company ”) ( TSX-V: RKV ) is pleased to announce that it has closed its previously announced non-brokered private placement (the “ Offer...
News, Short Squeeze, Breakout and More Instantly...
Rakovina Therapeutics Inc. Company Name:
RKV:CC Stock Symbol:
TSXVC Market:
Rakovina Therapeutics Inc. Website:
VANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the pres...
VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the ...
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“ Rakovina ” or the “ Company ”) (TSX-V: RKV) announces that in accordance with the terms of an indenture ente...